LncRNA Information | ||||||
---|---|---|---|---|---|---|
ID | EL0275 | Name | CCAL | Aliases | N/A | |
Species | Homo sapiens | Chromosome | N/A | Start site | N/A | |
End site | N/A | Chain | N/A | Exon NO. | N/A | |
Assembly | N/A | Class | N/A | NCBI accession | N/A | |
Ensembl | N/A | Sequence | N/A |
Disease | |||||||||
---|---|---|---|---|---|---|---|---|---|
Disease | Method | Sample | Expression pattern | Dysfunction type | Description | PMID | Source | ||
colorectal cancer | microarray, qPCR etc. | CRC tissue | up-regulated | interaction | We identified colorectal cancer-associated lncRNA (CCAL) as a key regulator of CRC progression. Patients whose tumours had high CCAL expression had a shorter overall survival and a worse response to adjuvant chemotherapy than patients whose tumours had low CCAL expression.Our results suggest that CCAL is a crucial oncogenic regulator involved in CRC tumorigenesis and progression. | 25994219 | Lnc2Cancer | ||
Interaction | |||||||||
---|---|---|---|---|---|---|---|---|---|
Interaction target | Level of interaction | Type of interaction | Description | PMID | Source | ||||
AP-2α | RNA-Protein | regulation | CCAL promoted CRC progression by targeting activator protein 2α (AP-2α), which in turn activated Wnt/β-catenin pathway. | 25994219 | |||||